Ozanimod

Ozanimod
Clinical data
Trade names	Zeposia
Other names	RPC-1063
AHFS/Drugs.com	Monograph
MedlinePlus	a620029
License data	EU EMA: by INN; US DailyMed: Ozanimod;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L04AE02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	19 hours
Identifiers
	IUPAC name 5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile;
CAS Number	1306760-87-1;
PubChem CID	52938427;
DrugBank	DB12612;
ChemSpider	34979946;
UNII	Z80293URPV;
KEGG	D10968; as HCl: D10967;
ChEMBL	ChEMBL3707247;
CompTox Dashboard (EPA)	DTXSID501026488 ;
ECHA InfoCard	100.247.081
Chemical and physical data
Formula	C23H24N4O3
Molar mass	404.470 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO;
	InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1; Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N;

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

The most common adverse reactions are upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

Ozanimod was approved for medical use in the United States in March 2020, in the European Union in May 2020, and in Australia in July 2020.